Guardant Health, Inc. (NASDAQ:GH) Expected to Post Quarterly Sales of $96.28 Million

Equities research analysts expect Guardant Health, Inc. (NASDAQ:GH – Get Rating) to post sales of $96.28 million for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Guardant Health’s earnings. The lowest sales estimate is $90.60 million and the highest is $101.82 million. Guardant Health reported sales of $78.67 million during the same quarter last year, which indicates a positive year-over-year growth rate of 22.4%. The firm is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Guardant Health will report full year sales of $465.35 million for the current financial year, with estimates ranging from $462.25 million to $469.10 million. For the next year, analysts expect that the company will post sales of $631.33 million, with estimates ranging from $611.69 million to $642.81 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Guardant Health.

Guardant Health (NASDAQ:GH – Get Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.24. Guardant Health had a negative return on equity of 53.91% and a negative net margin of 108.57%. The business had revenue of $108.10 million during the quarter, compared to analyst estimates of $98.72 million. During the same period in the prior year, the company posted ($0.94) EPS. The business’s revenue for the quarter was up 38.1% compared to the same quarter last year.

A number of equities analysts have issued reports on GH shares. Stifel Nicolaus decreased their price target on Guardant Health from $160.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, February 24th. Cowen cut their price objective on Guardant Health from $170.00 to $110.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. TheStreet downgraded Guardant Health from a “c-” rating to a “d+” rating in a research report on Monday, December 27th. SVB Leerink cut their price objective on Guardant Health from $170.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. Finally, Canaccord Genuity Group cut their price objective on Guardant Health from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, February 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Guardant Health presently has a consensus rating of “Buy” and an average target price of $138.50.

Shares of NASDAQ GH opened at $69.95 on Thursday. The stock has a fifty day moving average price of $64.55 and a two-hundred day moving average price of $84.56. The company has a debt-to-equity ratio of 1.76, a quick ratio of 5.57 and a current ratio of 5.72. The firm has a market cap of $7.13 billion, a P/E ratio of -17.49 and a beta of 0.68. Guardant Health has a 1 year low of $46.87 and a 1 year high of $169.43.

In other news, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $58.74, for a total value of $289,823.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.80% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Raymond James & Associates increased its position in Guardant Health by 3.1% during the third quarter. Raymond James & Associates now owns 199,767 shares of the company’s stock worth $24,973,000 after buying an additional 6,064 shares during the last quarter. Avestar Capital LLC increased its position in Guardant Health by 11.2% during the third quarter. Avestar Capital LLC now owns 5,319 shares of the company’s stock worth $665,000 after buying an additional 535 shares during the last quarter. Polar Asset Management Partners Inc. acquired a new position in Guardant Health during the third quarter worth $3,000,000. Pictet & Cie Europe SA increased its position in Guardant Health by 4.4% during the third quarter. Pictet & Cie Europe SA now owns 7,967 shares of the company’s stock worth $996,000 after buying an additional 339 shares during the last quarter. Finally, Coatue Management LLC increased its position in Guardant Health by 5.4% during the third quarter. Coatue Management LLC now owns 2,805,273 shares of the company’s stock worth $350,687,000 after buying an additional 144,070 shares during the last quarter. Institutional investors and hedge funds own 90.88% of the company’s stock.

About Guardant Health (Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

See Also